PDCD1 and glioblastoma: A phase II study in newly diagnosed GBM patients demonstrated that combining the anti-PD-1 antibody pembrolizumab with TMZ and tumor treatment resulted in an mPFS of 12.0 months compared with 5.8 months in case-matched controls [225].